Clinical Trial

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

Completed Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine if triple inhaled therapy with Budesonide/Glycopyrronium/Formoterol (BGF) and Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs. The main questions it aims to answer are: * Does BGF demonstrate a comparable effect to FUV in COPD participants? * What medical problems do participants experience when taking BGFand FUV?
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-28; most recent amendment 2026-01-29.
Status change: Recruiting → Completed 2026-01-29
Status change: Not Yet Recruiting → Recruiting 2025-04-25
Trial Details
NCT Number NCT06905483
Lead Sponsor Thammasat University
Conditions COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease, Triple Therapy, Lung Function
Enrollment 22 participants
Start Date 2025-04-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-02